Liothyronine-¹³C₉,¹⁵N  (Synonyms: Triiodothyronine-¹³C₉,¹⁵N; 3,3',5-Triiodo-L-thyronine-¹³C₉,¹⁵N; T3-¹³C₉,¹⁵N)

Liothyronine-¹³C₉,¹⁵N is the ¹³C and ¹⁵N labeled Liothyronine[1]. Liothyronine is an active form of thyroid hormone. Liothyronine is a potent thyroid hormone receptors TRα and TRβ agonist with Kis of 2.33 nM for hTRα and hTRβ, respectively[2][3][4].

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

660.90

C₆¹³C₉H₁₂I₃¹⁵NO₄

1213569-04-0

6893-02-3

I[13C]1=[13C](OC2=CC(I)=C(O)C=C2)[13C](I)=[13CH][13C]([13CH2][13C@@H]([13C](O)=O)[15NH2])=[13CH]1

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.  [Content Brief]

  [2]. Lin KH, et al. Stimulation of proliferation by 3,3',5-triiodo-L-thyronine in poorly differentiated human hepatocarcinoma cells overexpressing beta 1 thyroid hormone receptor. Cancer Lett. 1994 Oct 14;85(2):189-94.  [Content Brief]

  [3]. Bhat MK, et al. Conformational changes of human beta 1 thyroid hormone receptor induced by binding of 3,3',5-triiodo-L-thyronine. Biochem Biophys Res Commun. 1993 Aug 31195(1):385-92.  [Content Brief]

  [4]. Hiroaki Shiohara, et al. Discovery of novel indane derivatives as liver-selective thyroid hormone receptor β (TRβ) agonists for the treatment of dyslipidemia. Bioorg Med Chem. 2012 Jun 120(11):3622-34.  [Content Brief]